Top
This page is only for information of and use by registered medical practitioners. Other persons are advised not to act on the basis of information contained in this page. They are requested to consult registered medical practitioner.

Myotan (Azilsartan Medoxomil Tablet) is a angiotensin II receptor blocker (ARB) used in the therapy of hypertension. Myotan is marketed by JB Chemical and Pharmaceuticals limited and comes in two doses namely Myotan 40 mg and Myotan 80 mg.


Azilsartan inhibits the pressor effects of an angiotensin II infusion in a dose-related manner. Azilsartan blocks the vasoconstrictor and aldosterone secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is, therefore, independent of the pathway for angiotensin II synthesis


Azilsartan is a highly selective AT1 subtype angiotensin II receptor antagonist. Azilsartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. This action relaxes blood vessels and reduces high blood pressure..

Overview
Name of Product: MYOTAN® 40 / 80
Marketed by : JB Chemicals and Pharmaceuticals Ltd
Medicine composition: Azilsartan Kamedoxomil equivalent to Azilsartan Medoxomil 40 mg / 80mg
Prescription vs.OTC: Prescription by Doctor required
Dosage Form: Film coated tablets

Azilsartan is indicated for the treatment of hypertension in adult patients, either alone or in combination with other antihypertensive agents.

Recommended Dose
The recommended dose in adults is 80 mg taken orally once daily. Consider a starting dose of 40 mg for patients who are treated with high doses of diuretics. If blood pressure is not controlled with Azilsartan alone, additional blood pressure reduction can be achieved by taking Azilsartan with other antihypertensive agents. Azilsartan may be taken with or without food

Do not co-administer Aliskiren with Azilsartan in patients with diabetes.

Download Leaflet for details on Contraindications.

Myotan should be not used/carefully used following cases

  • Fetal Toxicity (Pregnancy)
  • Hypotension in Volume- or Salt-Depleted Patients
  • Impaired Renal Function

Download Leaflet to see the detailed warnings and precautions.

Azilsartan may have drug interactions with the following drugs

  • Non-steroidal Anti-Inflammatory Agents, including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)
  • Dual Blockade of the Renin-Angiotensin System (RAS)
  • Lithium

Download the Product Leaflet, to see the detailed drug interactions.

Studies show that treatment with Azilsartan is well-tolerated with an overall incidence of adverse reactions similar to placebo. The most common adverse event leading to discontinuation was hypotension/orthostatic hypotension. Some other side effects may include Gastrointestinal Disorders: nausea, diarrhea, general gisorders and Administration Site Conditions: asthenia, fatigue , musculoskeletal and connective tissue disorders: muscle spasm
Nervous System Disorders: dizziness, dizziness postural, respiratory, thoracic, and mediastinal disorders: cough

Download the Product Leaflet, to see the the detailed information on the Undesirable Side effects/ Overdose.

Download the Product Leaflet, to see the details on Pharmacodynamic and Pharmacokinetic Properties of Myotan 40/80

Contact us for further information

Myotan (Azilsartan Medoxomil Tablet) is a angiotensin II receptor blocker (ARB) used in the therapy of hypertension. Myotan is marketed by JB Chemical and Pharmaceuticals limited and comes in two doses namely Myotan 40 mg and Myotan 80 mg.


Azilsartan inhibits the pressor effects of an angiotensin II infusion in a dose-related manner. Azilsartan blocks the vasoconstrictor and aldosterone secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is, therefore, independent of the pathway for angiotensin II synthesis


Azilsartan is a highly selective AT1 subtype angiotensin II receptor antagonist. Azilsartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. This action relaxes blood vessels and reduces high blood pressure..

JOURNAL UPDATE


• Azilsartan: Novel Angiotensin Receptor Blocker

• Depressor and Anti-Inflammatory Effects of Angiotensin II Receptor Blockers in Metabolic and/or Hypertensive Patients With Coronary Artery Disease: A Randomized, Prospective Study (DIAMOND Study)

• Azilsartan Medoxomil Plus Chlorthalidone Reduces Blood Pressure More Effectively Than Olmesartan Plus Hydrochlorothiazide in Stage 2 Systolic Hypertension

• Azilsartan: Current Evidence and Perspectives in Management of Hypertension

• Azilsartan Improves Salt Sensitivity by Modulating the Proximal Tubular Na+-H+ Exchanger-3 in Mice

• Improvement of Diurnal Blood Pressure Variation by Azilsartan

• Effect of Azilsartan on Day-to-Day Variability in Home Blood Pressure: A Prospective Multicenter Clinical Trial

• Differential Pharmacology and Benefit/Risk of Azilsartan Compared to Other Sartans

• Effects of Olmesartan and Azilsartan on Albuminuria and the Intrarenal Renin-Angiotensin System

• Single-center Evaluation of the Single-Dose Pharmacokinetics of the Angiotensin II Receptor Antagonist Azilsartan Medoxomil in Renal Impairment

X
X